The trial evidence underpinning liraglutide 3.0 mg is robust. In the SCALE Obesity and Prediabetes randomized controlled trial published in the New England Journal of Medicine in 2015, Pi-Sunyer and colleagues demonstrated that 3.0 mg of liraglutide combined with lifestyle intervention produced significantly greater weight loss than placebo plus lifestyle measures. Maintenance studies, including the SCALE Maintenance trial, have underlined that continued treatment is needed to sustain that benefit, since weight regain typically becomes apparent within six to twelve months after GLP-1 discontinuation. But randomized trials enroll selected patients under ideal conditions, and the Taiwan surveillance study offers a window into what actually happens when the drug is deployed in routine care.

The technical design of the study matters for interpreting its results. As a single-arm, prospective, multicentre post-marketing surveillance study, it followed adults with obesity prescribed liraglutide in real clinical settings in Taiwan, tracking dose escalation, tolerability and weight outcomes. The headline finding is that clinically meaningful benefit may occur below the 3.0 mg target, supporting personalised rather than universal dose escalation. However, the commentary by Azhar Zafar and Carina Scarlata accompanying the paper urges caution in interpretation: this was a single-arm study that excluded participants who withdrew before follow-up, around half of the original cohort withdrew before week 13, and only 60 participants contributed to the week-26 analysis. The encouraging results in continuing users cannot establish comparative effectiveness, discontinuation outcomes or long-term weight maintenance.

The most consequential implementation finding is the cost signal. Forty-nine percent of participants who did not reach 3.0 mg cited medication cost as the barrier. In a health system where liraglutide is dispensed under surveillance but not universally reimbursed, the price of the drug functioned as a de facto dose-limiting mechanism. The commentary distinguishes this sharply from another common reason for submaximal dosing: gastrointestinal tolerability. When clinicians intentionally limit the dose because of nausea, vomiting or other adverse effects, that represents appropriate personalised medicine. When the dose is limited because the patient cannot afford the next increment, it represents an avoidable barrier to equitable treatment. The distinction is crucial for policy, because the two mechanisms demand entirely different responses.

Lower-dose success in this cohort may reflect four distinct mechanisms, according to the commentary. Lower exposure may have resulted from intentional dose limitation due to gastrointestinal tolerability, which is clinically appropriate; from cost constraints, which are a barrier to equitable care; from clinical preference based on individual risk-benefit assessment; or from other unmeasured factors. Without stratifying these mechanisms, it is impossible to tell whether lower-dose treatment represents a reproducible, clinically appropriate strategy or an artefact of selection bias. Analyses that relate achieved dose, duration, discontinuation reason and individual weight trajectory would help distinguish tolerable, sustainable treatment from treatment limited by systemic financial barriers.

The broader real-world evidence on GLP-1 persistence adds weight to these concerns. A narrative review published in Diabetes, Obesity and Metabolism by Heisey and colleagues documents substantial discontinuation rates for GLP-1 receptor agonists, with cost and tolerability emerging as principal drivers of dose escalation failure and early discontinuation. Real-world evidence increasingly documents the complex barriers to treatment persistence, and the Taiwan study illustrates how these barriers operate at the level of the individual prescription. When a patient stops escalating at 1.8 mg or 2.4 mg because the next step is unaffordable, the clinical record may show a stable dose, but the underlying story is one of treatment intensity rationed by ability to pay rather than clinical need.

Cost-limited dosing risks inequitable treatment intensity based on ability to pay rather than clinical need, and the commentary is explicit that obesity care must consider whether a sustainable dose can be achieved and maintained, not simply whether treatment is effective at the target dose. This reframing has significant implications for how success is measured in obesity medicine. A patient who achieves modest weight loss on a dose they can sustain for years may fare better in the long run than a patient who reaches the maximum dose but discontinues within months because of financial pressure. Reporting denominators at each time point, including weight outcomes for those who discontinue where feasible, would make the real-world picture more complete and allow clinicians and policymakers to see the full trajectory of treatment, not just the outcomes of those who persist.

The implications extend well beyond Taiwan. Although access pathways, reimbursement and service capacity differ between health systems, the affordability principle identified in Taiwan is directly applicable to publicly funded systems such as the NHS, where formulary restrictions and patient eligibility criteria similarly shape real-world practice patterns. Both contexts illustrate how healthcare policy and commissioning decisions function as de facto clinical decision-makers, determining which patients receive target doses and which receive cost-rationed submaximal doses. In systems where GLP-1 receptor agonists for obesity are restricted to specific specialist services or limited-duration prescribing, the same dynamic operates: the formulary, not the prescriber, may ultimately decide the dose.

What would better evidence look like? The commentary proposes that future pragmatic registries should follow participants for twelve to twenty-four months, sufficient time to capture seasonal patterns, medication persistence trends and longer-term weight trajectories. This duration matters because evidence indicates that weight regain typically becomes apparent within six to twelve months following GLP-1 discontinuation, as documented in a systematic review and nonlinear meta-regression published in EClinicalMedicine by Budini and colleagues. Registries should report dose exposure, persistence, discontinuation, outcomes, adverse events and barriers across socioeconomic and funding contexts. Only with this granularity can the field establish which submaximal doses are sustainable, for whom, and how obesity care can deliver equitable, durable benefit.

For now, the Taiwan study adds an important piece to the emerging real-world picture of GLP-1-based obesity care. Randomised studies support liraglutide 3.0 mg with lifestyle intervention, and maintenance studies underline the need to consider persistence rather than short-term loss alone. The surveillance data suggest that clinically meaningful benefit may be achievable below the maximum dose, opening the possibility of personalised dose selection that balances efficacy, tolerability and affordability. But the finding that cost was the reason for failed dose escalation in nearly half of those who did not reach 3.0 mg is a warning that cannot be ignored. If obesity treatment is to deliver on its promise, health systems must ensure that dose decisions are made on clinical grounds, not financial ones, and that the doses patients can afford are also the doses that can sustain their health over the long term.

Subject of Research: Medicine & Health

Article Title: Liraglutide Dose Affordability and Durability in Real‐World Obesity Care

Article References: Zafar, A., & Scarlata, C. (2026). Liraglutide Dose Affordability and Durability in Real‐World Obesity Care. Endocrinology, Diabetes & Metabolism, 9(6), Article e70364. https://doi.org/10.1002/edm2.70364

Image Credits: AI Generated

DOI: 10.1002/edm2.70364

Keywords: liraglutide, obesity, GLP-1 receptor agonists, drug affordability, real-world evidence, health equity, Taiwan, weight management, Dose, Affordability, Durability, Real

The research team, led by Alejandro Macchia and Daniel Ferrante of Argentina’s Ministry of Health together with Gianni Tognoni of the Permanent Peoples’ Tribunal in Rome, assembled a balanced panel of 9,910 specific commercial presentations spanning June 2021 to March 2026. That panel yielded 584,690 presentation-month observations, an unusually rich dataset for a question that is usually addressed through surveys or anecdote. Rather than asking people whether they had skipped doses, the researchers measured affordability directly from prices: they calculated how much of a single minimum pension would be required to purchase thirty defined daily doses of medicines in eight major outpatient therapeutic families, from antihypertensives to antipsychotics.

The methodological backbone of the study is an interrupted time-series design, a technique that treats a policy change as a natural experiment by comparing trends before and after a known intervention date. Because the panel included fixed effects for each specific commercial presentation, the models could control for the fact that different products have different baseline prices and different trajectories. The team divided the observation window into three phases: a pre-shock period, an acute-shock period immediately following December 2023, and a post-shock period through March 2026. This structure allowed them to separate the abrupt discontinuity caused by the shock from the slower drift in affordability that was already underway.

That pre-existing drift matters. Between June 2021 and March 2026, the median cumulative price increase across the medicines studied was 1,951 percent. Cumulative inflation over the same period reached 2,191 percent, while the minimum pension rose by only 1,502 percent. Those three numbers tell the story in miniature: drug prices roughly kept pace with the general price level, but the income of the most vulnerable pensioners lagged far behind. In other words, even before the December 2023 shock, affordability was deteriorating across all eight therapeutic families, a slow erosion that the shock then dramatically accelerated.

The acute phase of the shock produced a sharp fall in purchasing power. Argentina’s December 2023 policy package included a steep devaluation of the peso, the removal of price controls and subsidies, and aggressive fiscal adjustment, all of which fed into a burst of inflation that outpaced the periodic adjustments to the minimum pension. For a retiree depending on that pension, the arithmetic is unforgiving: when prices jump faster than income, the quantity of medicine a monthly budget can buy shrinks. The interrupted time-series models captured this as a sudden break in the affordability series, superimposed on the already negative pre-shock trend.

What is most striking is what happened afterward. By March 2026, long after the initial turbulence, the affordability burden remained above the pre-shock average in every one of the eight therapeutic families examined. The excess burden was not evenly distributed. Antiparkinsonian medicines showed the largest persistent gap, with affordability 31.5 percent worse than the pre-shock average, a difference the authors report with a 95 percent confidence interval of 14.8 to 50.5 percent. Antithrombotic medicines, which prevent the clots that cause strokes and heart attacks, carried a 22.8 percent excess burden (95 percent CI, 15.9 to 30.0), and antipsychotic medicines a 20.2 percent excess burden (95 percent CI, 14.5 to 26.2).

The therapeutic profile of the hardest-hit categories is itself a warning. Parkinson’s disease, cardiovascular disease and severe mental illness are precisely the conditions in which uninterrupted treatment is critical and in which interruption carries immediate clinical consequences. A retiree who cannot afford an antithrombotic faces a quantifiable rise in stroke risk; a patient with psychosis who runs out of medication risks relapse and hospitalization. The study did not measure whether patients actually skipped doses, but the affordability metric it does measure, the fraction of a minimum pension consumed by a standard monthly supply, is a well-established proxy for the financial barrier to adherence, and it moved decisively in the wrong direction.

The authors frame Argentina as a model case for studying medication-affordability vulnerability under macroeconomic shock, and the framing has implications well beyond one country. In high-inflation settings, they note, formal medicine availability can coexist with declining affordability: pharmacies may be fully stocked, yet the drugs remain out of reach for those on fixed incomes. This distinction challenges a common assumption in pharmaceutical policy that supply-side indicators, such as stockouts and registration status, are sufficient measures of access. Argentina’s experience shows that a country can maintain nominal availability while the effective access of its poorest citizens quietly collapses.

The policy prescription that emerges from the analysis is the need for countercyclical mechanisms that protect the purchasing power of vulnerable populations during macroeconomic adjustment. Pension indexation that lags inflation, as Argentina’s did over this period, effectively transfers the cost of stabilization onto pensioners, and the medicine price data reveal exactly where that transfer lands. The authors argue that pharmaceutical policy should not be treated as a passive bystander to macroeconomic reform; targeted subsidies, differential price regulation for essential chronic medicines, or automatic affordability-linked adjustments could buffer the shock for those least able to absorb it. Without such mechanisms, they suggest, stabilization programs will continue to generate hidden health costs that surface later as untreated disease.

The study has limitations worth noting, and the authors are transparent about its scope. It used aggregated, publicly available data rather than individual patient records, so it measures affordability rather than actual consumption, and it did not require ethics approval because no human subjects were involved. The analysis received no specific funding from any public, commercial or not-for-profit agency, and the authors declare no competing interests. Yet the scale and granularity of the panel, nearly 585,000 observations across eight therapeutic families and almost five years, give the findings a robustness that few affordability studies achieve. As other economies confront their own inflationary shocks and adjustment programs, the Argentine case stands as a quantitative demonstration that the price of macroeconomic discipline is not always counted in currency markets. Sometimes it is counted in monthly pension fractions, one prescription at a time, among people who can least afford to pay.

Subject of Research: The impact of shock economic policies on the affordability of essential medicines for older adults in Argentina

Article Title: Effects of shock economic policies on access to essential medicines among older adults in Argentina: an interrupted time-series analysis (2021–2026)

Article References: Macchia, A., Tognoni, G., & Ferrante, D. (2026). Effects of shock economic policies on access to essential medicines among older adults in Argentina: an interrupted time-series analysis (2021–2026). International Journal for Equity in Health. https://doi.org/10.1186/s12939-026-03023-6

Image Credits: AI Generated

DOI: 10.1186/s12939-026-03023-6

Keywords: Argentina, essential medicines, economic shock, drug affordability, older adults, minimum pension, inflation, interrupted time series, pharmaceutical policy, health equity, pharmacoeconomics, access to medicines